摘要
目的探讨恩替卡韦联合糖皮质激素在早期乙型肝炎相关肝衰竭中应用的临床疗效及安全性。方法选取2013年1月-2014年7月泰山医学院附属莱芜医院传染病分院收治的慢加急性肝衰竭患者60例为研究对象,随机分为治疗组(30例)、对照组(30例),治疗组在常规综合治疗及恩替卡韦抗病毒治疗的基础上加用糖皮质激素治疗,对照组给予常规综合治疗及恩替卡韦抗病毒治疗,观察两组患者的临床疗效及并发症发生情况。结果治疗8周后,与对照组患者比较,治疗组临床症状改善时间早,总胆红素明显降低,总胆固醇升高,凝血酶原活动度明显升高,两组比较差异有统计学意义(P<0.05)。治疗8周结束时,HBV DNA阴转率93%,与对照组(91%)相比,差异无统计学意义(P>0.05)。治疗组好转率(96.7%)明显高于对照组(76.7%)(P<0.05)。治疗组并发症发生率明显低于对照组(P<0.05)。结论恩替卡韦联合糖皮质激素对早期乙型肝炎相关肝衰竭患者疗效显著,安全性好。
Objective To investigate the clinical efficacy and safety of Entecavir combined with glucocorticoid in early stage of hepatitis B virus related liver failure. Methods Sixty patients with acute and chronic liver failure treated in Infections Diseases Branch of Laiwu Hospital Affiliated to Taishan Medical College from Jan. 2013 to Jul. 2014 were randomly divided into treatment group and control group, 30 cases in treatment group and 30 cases in control group. The treatment group was treated with conventional therapy, Entecavir and glucoco rticoid group was treated with conventional therapy and Entecavir. The clinical efficacy and complications between two groups were observed. Results After 8 weeks treatment, compared with control group, the clinical symptoms improved early, the total bilirubin was significantly lower, the total cholesterol was elevated, the prothrombin activity was significantly elevated in treatment group （P 〈 0.05）. At the end of the 8th week, the DNA HBV negative conversion rate was 93% in treatment group, compared with control group （91%）, the difference was not statistically significant （P 〉 0.05 ）. The improvement rate （96.7%） was significantly higher in treatment goup than that in control group （76.7%） （P 〈0.05）. The complication rate was sig- nificantly lower in treatment group than that in control group （P 〈 0.05）. Conclusion Effect of Entecavir combined with glucocorticoid in the early stage of HBV related liver failure is good and safe.
出处
《胃肠病学和肝病学杂志》
CAS
2015年第12期1505-1508,共4页
Chinese Journal of Gastroenterology and Hepatology
